Towards Healthcare
Medroxyprogesterone Acetate (MPA) Market to Grow at 9.13% CAGR till 2034

Medroxyprogesterone Acetate (MPA) Market Expands Amid 2025 Demand

Based on market forecasts, the medroxyprogesterone acetate (MPA) sector will expand from USD 1.14 billion in 2024 to USD 2.75 billion by 2034, experiencing a CAGR of 9.13%. The rising prevalence of gynecological disorders is estimated to drive the growth of the market. North America led the global market owing to high healthcare expenditure and insurance coverage.

Content

  • Insight Code: 6264
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Kesiya Chacko is an accomplished market research professional with over 4+ years of experience in the healthcare industry, known for delivering actionable insights and strategic analysis that empower healthcare organizations to navigate complex, rapidly evolving markets.

Kesiya began her research career with Precedence Research, where she built a strong foundation in pharmaceutical and healthcare market analysis. Today, she plays an integral role at Towards Healthcare, contributing to in-depth, client-centric research initiatives. She also brings her expertise to Statifacts, supporting broader research functions with a focus on cross-sector healthcare trends and data interpretation.

Her commitment to high-quality analysis, combined with a strong grasp of regulatory and market dynamics, makes her a trusted contributor to healthcare firms seeking future-ready, data-backed decisions. Kesiya’s work spans the analysis of industry trends, competitive benchmarking, and evaluation of regulatory and innovation-driven shifts.

Talk to us
FAQ's

The medroxyprogesterone acetate (MPA) market currently in 2025 records USD 1.24 billion and is anticipated to grow to USD 2.75 billion by 2034, advancing at a CAGR of 9.13% from 2024 to 2034.

North America is leading the medroxyprogesterone acetate (MPA) market due to the growing demand for long-acting contraceptives, the prevalence of gynecological disorders, and government initiatives promoting women health, drive market growth.

Some key players include Pfizer Inc., Bayer AG, Mylan N.V. (Viatris), Cipla Limited, Teva Pharmaceutical Industries Ltd., Hetero Labs Limited, Fresenius Kabi AG, and Sandoz International GmbH etc.

MPA is a synthetic progestin hormone used in contraceptives, hormone replacement therapy, and the treatment of gynecological disorders such as endometriosis and irregular menstruation. It is available in oral tablets, injectable, and subcutaneous formulations.

Personalized Medicine Coalition, The Menopause Society, Government of Canada, Food and Drug Administration, International Menopause Society (IMS), clinicaltrials.gov, North American Menopause Society, WHO, JAMA, GOV.UK
Any Questions